$OMDA

Duffy Sean P. sold $510K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 21,570 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($20.90–$24.81, $0.51M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Aug 11, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OMDA
Neutral
medium confidence
Mentioned
$OMDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The only new fact is the disclosed sale size, timing (Aug 7 to Aug 10), and post-transaction holdings (411,861 shares). There is no new company-specific fundamental information in the text.

02

Market read

Traders may treat this as a minor sentiment datapoint, but it is unlikely to drive a durable repricing without additional fundamental catalysts.

03

What to watch

The filing does not state reasons for the sale, and the price range ($20.90 to $24.81) spans multiple days, limiting inference about timing or valuation views.

Relevance 4/10Novelty 3/10Timing: filed Aug 11, covering sales from Aug 7 to Aug 10

Background

This is an SEC Form 4 insider transaction by Omada Health CEO Sean P. Duffy, reporting open-market sales under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$OMDANeutralMedium confidence
Context

Omada Health CEO Sean P. Duffy sold about $509.6K of OMDA shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows a planned sale (10b5-1) with no accompanying guidance, deal, or regulatory event; insider selling can still be read as signal, but the pre-arranged nature reduces interpretive weight.

Market effects

No direct sector read-through beyond routine insider activity in digital health.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; the disclosure may not reflect new negative information.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction; CEO Sean P. Duffy sold shares totaling about $509.6K.

  • Sean P. Duffy

    CEO and officer/director who executed the open-market sales under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHighAI 9/10

Omada Health (OMDA) Q2 2026 Earnings Call Transcript

Omada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.

$OMDAHigh

Omada Health, Inc. (OMDA): Results of Operations and Financial Condition

Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Ch